Transcriptional Signatures Sensitive to Cognition-Improving Pharmacological Treatments in Fragile X Syndrome

June 27, 2022

This team is defining Fragile X “molecular signatures” to use as biomarkers. They’ll test CBD and other drugs in mice and compare findings to human brain data.

Read More »
Andres Ozaita, PhD

Targeting the Endocannabinoid System in Adult Fragile X Mice

September 15, 2014

With a $90,000 grant from the FRAXA Research Foundation from 2013-2014, Dr. Andres Ozaita led a team to test rimonabant’s ability to blockade the CB1 receptor. Blocking CB1 has shown potential to reverse most symptoms of disease in mice bred to mimic Fragile X syndrome.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)